# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹998.8 Cr** FY26 (+32.2%) · **₹265.6 Cr** Q4 FY26 (+21.2%) * **Adjusted EBITDA:** **₹238.2 Cr** FY26 (+37.6%) · **23.8%** FY26 Margin (+100 bps) * **Adjusted PAT:** **₹128.3 Cr** FY26 (+74.6%) · **₹35 Cr** Q4 FY26 (+27.4%) * **Cash Metrics:** **₹233 Cr** Operating Cash Flow · **₹68 Cr** Free Cash Flow · **₹500 Cr** Cash Balance * **Efficiency:** **22.8%** Pre-tax ROCE (vs 19.9% YoY) · **₹2,598** Revenue Per Treatment (+13.3%) ## B. Revenue & Profitability * **Operating Leverage:** Adjusted PAT growth significantly outpaced revenue gains, reflecting enhanced scale and a sharp increase in PAT margins. * **Q4 Margin Impact:** Quarterly EBITDA margins were suppressed by a **₹10 Cr** one-time ECL provision; normalized margins would have reached **25%**. * **Volume & Yield Drivers:** Top-line momentum was supported by double-digit growth in treatment volumes and improved realization per treatment. ## C. Margins & Leverage * **Accounting Reclassification:** A shift in treating repair and maintenance as operating rather than capitalized expenses contributed to higher "other expenses." * **International Margin Profile:** Global expansion is projected to deliver superior margins and ROCE compared to peers by utilizing the existing domestic platform. * **Temporary Cost Overhang:** Current India standalone costs are inflated by corporate expenses for IT and business development that support the international ramp-up. ## D. Capital Expenditure * **Aggressive Expansion:** Capital allocation increased by nearly half YoY to **₹165 Cr**, distributed across India, the Philippines, and Uzbekistan. * **Regional Unit Economics:** India requires **₹10-11 lakhs** per bed (4-year payback), while the Philippines is more capital-intensive at **₹40-45 lakhs** per bed. * **High-Velocity Markets:** Uzbekistan clinics show superior capital efficiency with a rapid payback period of **1 to 1.5 years** on an investment of **₹18-20 lakhs** per bed. * **Strategic Deployment:** Management is actively evaluating ROCE-accretive opportunities to deploy its substantial cash reserves for further platform strengthening. --- # 2. Business Model & Operations ## A. Key Figures * **Total Treatment Volume:** **3,844,658 sessions** (+16.6% YoY) * **Active Guest Count:** **36,981 patients** (+11.8% YoY) * **Network Scale:** **468 clinics** (vs. 447 YoY) * **Working Capital:** **83 days** (from 92) · **116 AR days** (14-day reduction) ## B. Clinical Service Delivery * **Non-Discretionary Revenue Model:** Business relies on a chronic, life-sustaining service profile where patients require lifelong, high-frequency treatment (typically thrice weekly). * **Strategic Specialization:** Management maintains a strict **100% focus** on dialysis delivery, explicitly ruling out expansion into pre-dialysis or CKD management adjacencies. * **Scalable "Shop-in-Shop" Framework:** Transitioned to a captive model partnering with private hospitals, utilizing a "codified operating system" to ensure predictable clinical outcomes across diverse geographies. * **Academic & Clinical Rigor:** Quality is benchmarked via a Medical Advisory Board and active scientific contributions, including **two papers and eight abstracts** published in FY26. ## C. Network & Capacity * **Fixed-Capacity Dynamics:** Growth is structurally capped at **three cycles per day** per machine; once optimized, expansion is strictly dependent on adding new machines or locations. * **Retail-Style Expansion:** Due to hospital real estate constraints, the company employs a retail-like growth strategy, prioritizing new clinic additions to bypass physical capacity ceilings. * **Operational Footprint:** The Indian network currently averages **7,000 sessions per clinic** annually, typically operating with **10 to 11 machines** per site. * **Volume-Centric Evaluation:** Management prioritizes treatment volume over net center counts as the primary KPI, noting that patients typically migrate to nearby centers if a specific location closes. ## D. Customer Metrics & Efficiency * **Protocol-Driven Growth:** Treatment volume growth outpaced patient base growth, driven by nephrologist referrals and patients progressing to higher-frequency treatment protocols. * **Mono-line Scalability:** Standardized protocols delivered by technicians allow the model to penetrate Tier 2–4 markets where specialist nephrologist availability is otherwise a barrier. * **Efficiency Gains:** Significant improvements in liquidity metrics were driven largely by performance in the Philippines, resulting in a notable reduction in the cash conversion cycle. * **Standardized Culture:** The "Blue Book" manual serves as the operational blueprint to ensure consistent "Guest Care" and clinical empathy across the expanding 468-clinic network. --- # 3. Geography & Segment Mix ## A. Key Figures * **Global Network:** **524** clinics · **335** cities · **5** countries * **Revenue Per Treatment (RPT):** **₹2,598** (+13.3% YoY) * **International Revenue Mix:** **42%** of total (vs. 32% YoY) * **Patient Base:** **37,000** active guests * **Saudi Arabia JV Performance:** **-₹3 Cr** (Loss) ## B. India Market Leadership * **Dominant Market Position:** Operates the largest dialysis network in India and Asia, ranking fifth globally by volume. * **Strategic Expansion:** Growth focused on brownfield takeovers to secure established patient bases and accelerate break-even, supplemented by selective greenfield setups. * **Maturity Profile:** Management highlighted the long-term nature of the model, noting it took **10 years** for Indian operations to reach EBITDA positivity and **13 years** for PAT positivity. ## C. International Expansion * **High-Yield Arbitrage:** Leveraging a low-cost Indian operational platform to enter markets with significantly higher price points; RPT in the Philippines and Uzbekistan is estimated at **3x** the Indian rate. * **Regional Footprint:** Established as the third-largest network in the Philippines (44 clinics) and operates high-ROCE projects in Uzbekistan and Nepal. * **Saudi Arabia Entry:** Currently in a two-year investment phase via a **51/49 JV**; bidding on government tenders (EOI stage) while navigating accounting reclassifications for line-by-line consolidation. * **Disciplined Selection:** Entry into new geographies (3-5 under exploration) is governed by strict criteria regarding reimbursement viability, political stability, and cash repatriation. ## D. Public-Private Partnerships (PPP) * **Portfolio Diversification:** PPP segment remains a core pillar, with growth driven by existing projects in Karnataka and new government centers in Bihar. * **Contract Management:** Actively exploring new contracts to offset potential non-renewals; successfully completed **two renewals** in Uttarakhand to date. ## E. Segment Performance * **Mix-Driven Growth:** Robust RPT improvement is primarily attributed to the rising contribution of international revenue rather than domestic price hikes. * **Consolidated Focus:** Management urges a shift toward consolidated evaluation to reflect the company’s evolution into a global platform play and to mitigate standalone "noise." * **Operational Efficiency:** Competitive edge in developed markets maintained by managing manpower costs through the company's strong presence in key labor-supply geographies. --- # 4. Strategic Initiatives ## A. Key Figures * **Philippines Acquisition Scale:** **14-15** beds per clinic · **600-800** monthly sessions * **M&A Pipeline:** **12-15** targeted acquisitions in Philippines (FY) · **550-600** addressable unorganized centers * **AI Deployment:** **50** clinics currently active with Reformmed.AI ## B. Growth Levers * **Multi-Pronged Expansion:** Growth is anchored by volume/price increases in existing clinics, predictable regional roll-ups, and high-impact entries into new sovereign markets or PPPs. * **Operating Leverage & ROCE:** Strategy prioritizes scale-driven asset utilization, leveraging higher patient volumes to enhance return on capital employed. * **Full-Spectrum Kidney Care:** Beyond dialysis, the firm is developing a **CKD prevention platform** targeting **Stages 1-4** to delay dialysis onset and capture the early-stage patient funnel. ## C. M&A & Consolidation * **Philippines Roll-up Strategy:** Following a successful mid-size acquisition, management is aggressively targeting the fragmented local market to consolidate unorganized centers. * **Infrastructure Support:** Increasing investments in IT and localized support operations (supply chain and BD) to integrate and scale the Philippines footprint. ## D. Technology & AI * **Digital Differentiation:** Positioning as a global leader in dialysis tech through **Reformmed.AI**, an application designed to automate operational monitoring and enhance clinical outcomes. * **Network-Wide Integration:** Plans are underway to expand AI capabilities across the entire global network following the initial pilot phase. ## E. Talent & Training * **Vertical Integration of Labor:** Maintains a competitive moat against global peers via **Enpidia training academies**; these facilities secure a proprietary pipeline of nursing and paramedic staff from key labor-exporting regions. * **Global BD Bench:** Active hiring of international personnel to accelerate business development and sovereign-level project execution. --- # 5. Industry Trends & Demand ## A. Key Figures * **Market Opportunity (India):** **12.4 Cr** CKD patients · **7%** diagnosis rate · **3 Lakh** patients on dialysis out of **42 Lakh** ESRD cases * **Global Market Value:** **$80 Bn** * **Pricing Benchmarks (Per Treatment):** **$22** India · **$60** Uzbekistan · **$111** Philippines * **Reimbursement Hikes:** **+35%** CGHS (India) · **+58%** PhilHealth (Philippines) * **Market Share:** **~50%** of India’s organized dialysis market ## B. Chronic Disease Burden & GLP-1 Impact * **Underpenetrated Demand:** Massive gap between ESRD prevalence and treatment access in India; growth is structurally driven by rising diabetes and hypertension. * **GLP-1 Resilience:** Management views GLP-1 drugs as a "single time lag" rather than a TAM reduction; impact is negligible in developed markets and irrelevant to emerging markets for the next **10–15 years**. * **Life-Sustaining Necessity:** Dialysis remains the primary treatment modality due to the complexity and rarity of kidney transplants. ## C. Pricing & Reimbursement Dynamics * **Global Pricing Arbitrage:** India remains the lowest-cost provider globally; international expansion is the primary lever for increasing Average Revenue Per Treatment (RPT). * **Policy-Driven Revenue:** RPT growth is lumpy and dependent on government/insurance updates rather than annual hikes; the recent **58%** increase in the Philippines will fully materialize in FY 2026. * **Operational Moat:** High fixed costs and low price points necessitate massive scale and 100% operational focus to maintain sustainable margins. ## D. Competitive Position & Market Evolution * **Consolidation Runway:** The Philippines presents a multi-decadal opportunity with a "tail" of **550–600** unorganized clinics ripe for aggregation. * **Structural Shift:** India is transitioning toward standalone clinics (moving away from hospital-based units) due to real estate constraints and patient proximity needs, mirroring developed market trends. * **Competitive Intensity:** While higher reimbursement in the Philippines may attract global and Indian peers, NephroPlus leverages a six-year local track record to defend its position. * **Pure-Play Strategy:** The company maintains a **100%** strategic focus on the dialysis sector across all geographies. --- # 6. Risks & Regulatory Factors ## A. Key Figures * **ECL Provision:** **₹10 Cr** One-time provision for aged accounts * **FX Tailwinds:** **5%** Philippine Peso appreciation · **7%** Uzbek currency appreciation * **Pricing Action:** **58%** Price increase in Philippines (Oct 2024 impact) ## B. Credit & Provisioning * **Prudential Provisioning:** Management recognized a one-time charge related to two specific institutional accounts aged 4–5 years to prevent future earnings volatility. * **Structural Recovery Challenges:** The provision reflects inherent difficulties in recovering funds from private hospitals and institutions within the dialysis sector. * **Governance & Modeling:** The charge was determined via a standardized model ratified by **KPMG**, contributing to a sharp spike in quarterly "other expenses." ## C. Licensing & Compliance * **High-Barrier International Markets:** The Philippines presents significant regulatory complexity compared to India, requiring standalone premises and a multi-tiered licensing regime. * **Operational Rigor:** Expansion in the Philippines is contingent on securing **Department of Health** and **PhilHealth** empanelment, alongside **five additional licenses** (e.g., LTO) requiring annual renewal. ## D. Contract Renewal Risks * **PPP Pipeline Exposure:** Two Public-Private Partnership contracts face renewal in **2026**, including clinics in Uttarakhand and a phase of the Andhra Pradesh tender. * **Tendering Timelines:** The Uttarakhand tender is currently active and expected to conclude within **2–4 months**, with the company maintaining operations during the interim. * **Saudi Arabia EOI:** A new Expression of Interest has been released in Saudi Arabia; management requires **1–2 quarters** to evaluate terms before forecasting capacity growth. ## E. Currency & Macro * **Exchange Rate Benefits:** Financial performance was bolstered by favorable movements in the Peso and Uzbek currency, alongside the full-year realization of significant pricing adjustments in the Philippines. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue CAGR Guidance:** **15% to 20%** Long-term (3-4 years) * **Annual Clinic Additions (India):** **40 to 50** Gross new centers * **Annual Clinic Additions (Philippines):** **12 to 15** New centers * **Market Opportunity:** **13% CAGR** Indian dialysis population growth · **5.2 lakh** Projected patients by 2029 ## B. Long-term Growth Strategy * **Sustainable Top-line Momentum:** Management reaffirmed a robust double-digit CAGR outlook supported by disciplined capital deployment and international platform scaling. * **Addressable Market Gap:** Growth is underpinned by a significant domestic supply-demand imbalance, with a projected requirement of **5,500 clinics** by 2029 to service the rising patient base. * **Expansion Methodology:** Projected clinic growth focuses exclusively on organic in-center expansion and roll-ups, excluding potential upside from **large PPP projects or major acquisitions**. ## C. International Pipeline & Execution * **Saudi Arabian Entry:** The first Riyadh-based clinic is scheduled to launch within **two months**, serving as a clinical showcase ahead of upcoming government RFP tenders. * **Middle East Visibility:** Financial performance in Saudi Arabia is expected to remain steady for several quarters, with significant contract-driven scaling potentially taking **up to a year** to materialize. * **Philippines Resilience:** Management remains confident in its expansion targets despite new market entrants, citing a high volume of available acquisition targets. ## D. Profitability & Capital Allocation * **FY27 Outlook:** Positive trajectory for revenue and margins driven by network effects, treatment volume growth, and an expanding patient pool. * **Capital Discipline:** Management maintains a strict allocation framework based on strategic criteria, opting not to provide specific capex guidance for the next fiscal year.